Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson's Disease

Tânia M Bovolenta, Sônia Maria Cesar de Azevedo Silva, Roberta Arb Saba, Vanderci Borges, Henrique Ballalai Ferraz, Andre C Felicio, Tânia M Bovolenta, Sônia Maria Cesar de Azevedo Silva, Roberta Arb Saba, Vanderci Borges, Henrique Ballalai Ferraz, Andre C Felicio

Abstract

Parkinson's disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than four million people. Typically, it affects individuals above 45, when they are still productive, compromising both aging and quality of life. Therefore, the cost of the disease must be identified, so that the use of resources can be rational and efficient. Additionally, in Brazil, there is a lack of research on the costs of neurodegenerative diseases, such as PD, a gap addressed in this study. This systematic review critically addresses the various methodologies used in original research around the world in the last decade on the subject, showing that costs are hardly comparable. Nonetheless, the economic and social impacts are implicit, and important information for public health agents is provided.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Search, selection, and inclusion of papers for critical analysis of studies on economic PD evaluation in online platforms.
Figure 2
Figure 2
Number of publications on PD costs over the past 10 years. Scopus = 397 papers; Pubmed = 125 papers; Selected = 30.

References

    1. Catalá-López F., García-Altés A., Alvarez-Martín E., Gènova-Maleras R., Morant-Ginestar C., Parada A. Burden of disease and economic evaluation of healthcare interventions: are we investigating what really matters? BMC health services research. 2011;11, article 75 doi: 10.1186/1472-6963-11-75.
    1. Liu S.-Y., Wu J.-J., Zhao J., et al. Onset-related subtypes of Parkinson's disease differ in the patterns of striatal dopaminergic dysfunction: a positron emission tomography study. Parkinsonism and Related Disorders. 2015;21(12):1448–1453. doi: 10.1016/j.parkreldis.2015.10.017.
    1. Guo X., Song W., Chen K., et al. Gender and onset age-related features of non-motor symptoms of patients with Parkinson's disease—a study from Southwest China. Parkinsonism & Related Disorders. 2013;19(11):961–965. doi: 10.1016/j.parkreldis.2013.06.009.
    1. Nero C. R. D. What is health economics? In: Piola S. F., Vianna S. M., editors. Health Economics: Concepts and Contributions to Health Management. chapter I. Brasília, Brazil: Ipea; 2002. pp. 5–23.
    1. Vanni T., Luz P. M., Ribeiro R. A., Novaes H. M. D., Polanczyk C. A. Economic evaluation in health: applications in infectious diseases. Cadernos de saúde pública. 2009;25(12) doi: 10.1590/s0102-311x2009001200002.
    1. Brazil Ministry of Health. Methodological Guidelines: Economic Evaluation of Health Technologies. Brasília, Brazil: Brazil Ministry of Health; 2009. .
    1. Moraes E., Campos G. M., Figlie N. B., Laranjeira R. R., Ferraz M. B. Introductory concepts of health economics and the social impact of alcohol abuse. Revista Brasileira de Psiquiatria. 2006;28(4):321–325. doi: 10.1590/s1516-44462006000700014.
    1. Secoli S. R., Nita M. E., Ono-Nita S. K., Nobre M. Health technology assessment. II. Cost effectiveness analysis. Arquivos de Gastroenterologia. 2010;47(4):329–333. doi: 10.1590/S0004-28032010000400002.
    1. Tarride J.-E., Blackhouse G., Bischof M., et al. Approaches for economic evaluations of health care technologies. Journal of the American College of Radiology. 2009;6(5):307–316. doi: 10.1016/j.jacr.2009.01.011.
    1. Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clinical and Molecular Hepatology. 2014;20(4):327–337. doi: 10.3350/cmh.2014.20.4.327.
    1. Rice D. P. Cost of illness studies: what is good about them? Injury Prevention. 6(3):177–179. doi: 10.1136/ip.6.3.177.
    1. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy. 2006;77(1):51–63. doi: 10.1016/j.healthpol.2005.07.016.
    1. Gustavsson A., Svensson M., Jacobi F., et al. Cost of disorders of the brain in Europe 2010. European Neuropsychopharmacology. 2011;21(10):718–779. doi: 10.1016/j.euroneuro.2011.08.008.
    1. Organização Mundial da Saúde. Financing Health Systems: The Road to Universal Coverage. Genebra, Switzerland: Organização Mundial da Saúde; 2010. .
    1. Dorsey E. R., Constantinescu R., Thompson J. P., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–386. doi: 10.1212/01.wnl.0000247740.47667.03.
    1. Morris M. E., Watts J. J., Iansek R., et al. Quantifying the profile and progression of impairments, activity, participation, and quality of life in people with Parkinson disease: protocol for a prospective cohort study. BMC Geriatrics. 2009;9(1, article no. 2) doi: 10.1186/1471-2318-9-2.
    1. Barbosa M. T., Caramelli P., Maia D. P., et al. Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambuí Study) Movement Disorders. 2006;21(6):800–808. doi: 10.1002/mds.20806.
    1. Andlin-Sobocki P., Jönsson B., Wittchen H. U., Olesen J. Cost of disorders of the brain in Europe. European Journal of Neurology. 2005;12(supplement 1):1–27.
    1. Zhao Y. J., Tan L. C. S., Au W. L., et al. Estimating the lifetime economic burden of Parkinson's disease in Singapore. European Journal of Neurology. 2013;20(2):368–374. doi: 10.1111/j.1468-1331.2012.03868.x.
    1. Johnson S., Davis M., Kaltenboeck A., et al. Early retirement and income loss in patients with early and advanced Parkinsons disease. Applied Health Economics and Health Policy. 2011;9(6):367–376. doi: 10.2165/11596900-000000000-00000.
    1. Cubo E., Alvarez E., Morant C., et al. Burden of disease related to Parkinson's disease in Spain in the year 2000. Movement Disorders. 2005;20(11):1481–1487. doi: 10.1002/mds.20622.
    1. Kowal S. L., Dall T. M., Chakrabarti R., Storm M. V., Jain A. The current and projected economic burden of Parkinson's disease in the United States. Movement Disorders. 2013;28(3):311–318. doi: 10.1002/mds.25292.
    1. Kaltenboeck A., Johnson S. J., Davis M. R., et al. Direct costs and survival of medicare beneficiaries with early and advanced parkinson's disease. Parkinsonism and Related Disorders. 2012;18(4):321–326. doi: 10.1016/j.parkreldis.2011.11.015.
    1. Huse D. M., Schulman K., Orsini L., Castelli-Haley J., Kennedy S., Lenhart G. Burden of illness in Parkinson's disease. Movement Disorders. 2005;20(11):1449–1454. doi: 10.1002/mds.20609.
    1. Lökk J., Borg S., Svensson J., Persson U., Ljunggren G. Drug and treatment costs in Parkinson's disease patients in Sweden. Acta Neurologica Scandinavica. 2012;125(2):142–147. doi: 10.1111/j.1600-0404.2011.01517.x.
    1. Jennum P., Zoetmulder M., Korbo L., Kjellberg J. The health-related, social, and economic consequences of parkinsonism: A Controlled National Study. Journal of Neurology. 2011;258(8):1497–1506. doi: 10.1007/s00415-011-5969-1.
    1. Noyes K., Liu H., Li Y., Holloway R., Dick A. W. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries. Movement Disorders. 2006;21(3):362–372. doi: 10.1002/mds.20727.
    1. Cordato D. J., Schwartz R., Abbott E., Saunders R., Morfis L. A comparison of health-care costs involved in treating people with and without Parkinson's disease in Southern Sydney, New South Wales, Australia. Journal of Clinical Neuroscience. 2006;13(6):655–658. doi: 10.1016/j.jocn.2005.09.006.
    1. Bhattacharjee S., Sambamoorthi U. Co-occurring chronic conditions and healthcare expenditures associated with Parkinson's disease: a propensity score matched analysis. Parkinsonism and Related Disorders. 2013;19(8):746–750. doi: 10.1016/j.parkreldis.2013.02.019.
    1. Winter Y., Von Campenhausen S., Reese J. P., et al. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study. Neurodegenerative Diseases. 2010;7(6):365–372. doi: 10.1159/000302644.
    1. Vossius C., Gjerstad M., Baas H., Larsen J. P. Drug costs for patients with Parkinson's disease in two different European countries. Acta Neurologica Scandinavica. 2006;113(4):228–232. doi: 10.1111/j.1600-0404.2005.00574.x.
    1. Winter Y., von Campenhausen S., Brozova H., et al. Costs of Parkinson's disease in Eastern Europe: a Czech cohort study. Parkinsonism and Related Disorders. 2010;16(1):51–56. doi: 10.1016/j.parkreldis.2009.07.005.
    1. McCrone P., Allcock L. M., Burn D. J. Predicting the cost of Parkinson's disease. Movement Disorders. 2007;22(6):804–812. doi: 10.1002/mds.21360.
    1. Spottke A. E., Reuter M., Machat O., et al. Cost of illness and its predictors for Parkinson's disease in Germany. PharmacoEconomics. 2005;23(8):817–836. doi: 10.2165/00019053-200523080-00007.
    1. Leibson C. L., Hall Long K., Maraganore D. M., et al. Direct medical costs associated with Parkinson's disease: a population-based study. Movement Disorders. 2006;21(11):1864–1871. doi: 10.1002/mds.21075.
    1. Ragothaman M., Govindappa S. T., Rattihalli R., Subbakrishna D. K., Muthane U. B. Direct costs of managing Parkinson's disease in India: concerns in a developing country. Movement Disorders. 2006;21(10):1755–1758. doi: 10.1002/mds.21035.
    1. Winter Y., Campenhausen S. V., Popov G., et al. Costs of illness in a Russian cohort of patients with parkinsons disease. PharmacoEconomics. 2009;27(7):571–584. doi: 10.2165/11310160-000000000-00000.
    1. Zhao Y. J., Tan L. C. S., Li S. C., et al. Economic burden of Parkinson's disease in Singapore. European Journal of Neurology. 2011;18(3):519–526. doi: 10.1111/j.1468-1331.2010.03210.x.
    1. Tamás G., Gulácsi L., Bereczki D., et al. Quality of life and costs in Parkinson's disease: a cross sectional study in Hungary. PLoS ONE. 2014;9(9) doi: 10.1371/journal.pone.0107704.e107704
    1. Yoritaka A., Fukae J., Hatano T., Oda E., Hattori N. The direct cost of Parkinson disease at Juntendo medical university hospital, Japan. Internal Medicine. 2016;55(2):113–119. doi: 10.2169/internalmedicine.55.4484.
    1. Johnson S. J., Kaltenboeck A., Diener M., et al. Costs of parkinson's disease in a privately insured population. PharmacoEconomics. 2013;31(9):799–806. doi: 10.1007/s40273-013-0075-0.
    1. Vargas A. P., Carod-Artal F. J., Nunes S. S., Melo M. Disability and use of healthcare resources in Brazilian patients with Parkinson's disease. Disability and Rehabilitation. 2008;30(14):1055–1062. doi: 10.1080/17483100701456079.
    1. Bach J.-P., Riedel O., Klotsche J., Spottke A., Dodel R., Wittchen H.-U. Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease. Journal of the Neurological Sciences. 2012;314(1-2):41–47. doi: 10.1016/j.jns.2011.11.002.
    1. Martínez-Martin P., Rodriguez-Blazquez C., Paz S., et al. Parkinson symptoms and health related quality of life as predictors of costs: A Longitudinal Observational Study with Linear Mixed Model Analysis. PLOS ONE. 2015;10(12) doi: 10.1371/journal.pone.0145310.e0145310
    1. von Campenhausen S., Winter Y., Rodrigues e Silva A., et al. Costs of illness and care in Parkinson's disease: an evaluation in six countries. European Neuropsychopharmacology. 2011;21(2):180–191. doi: 10.1016/j.euroneuro.2010.08.002.
    1. Winter Y., Balzer-Geldsetzer M., Spottke A., et al. Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany. European Journal of Neurology. 2010;17(9):1156–1163. doi: 10.1111/j.1468-1331.2010.02984.x.
    1. Winter Y., Balzer-Geldsetzer M., von Campenhausen S., et al. Trends in resource utilization for Parkinson's disease in Germany. Journal of the Neurological Sciences. 2010;294(1-2):18–22. doi: 10.1016/j.jns.2010.04.011.
    1. Wang G., Cheng Q., Zheng R., et al. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China. Movement Disorders. 2006;21(9):1439–1443. doi: 10.1002/mds.20999.
    1. Dodel R., Jönsson B., Reese J. P., et al. Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. Movement Disorders. 2014;29(2):169–176. doi: 10.1002/mds.25571.
    1. Langer A. A framework for assessing Health Economic Evaluation (HEE) quality appraisal instruments. BMC health services research. 2012;12, article no. 253 doi: 10.1186/1472-6963-12-253.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe